Navigation Links
Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
Date:10/30/2007

l results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues;
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European ... market in Europe with analysis and forecast of revenue. ... grow from around $509.4 million in 2013 to $657.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
(Date:7/27/2014)... The report provides market analysis of ... Analysis (Commercial Aviation And Defense Aviation Landing Gear, ... Forecasts 2014 - 2019." The report covers the ... the market during the study period. It also ... are currently prevailing in the global market. , ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... Although Cigarette and Tobacco ... two companies, heavy government regulation results in extremely ... Little, “Demand for cigarettes has declined over the ... frequent anti-smoking campaigns, increasing regulation and higher excise ... to fall at a compound annual 0.8% over ...
(Date:7/27/2014)... Dallas, Texas (PRWEB) July 27, 2014 One ... demand for genomics products from the Asia Pacific (APAC) region. ... is expected to generate high demand for genomics solutions, thereby ... Genomics market will grow at a CAGR of 11.21 ... most important driver of the market is an increase in ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5
... A ... Medicine, Athletes, Performance, and the Pensacola Fire Department began in April to collect biomechanical data ... ... -- A call comes in to the local Pensacola Fire Department to be first on ...
... and middle-income countries fare the worst, statistics show , THURSDAY, ... death rates, researchers have found that 97 percent of deaths ... in poor and middle-income countries. , While much of the ... of the deaths in this age group occur because of ...
... , TEMECULA, Calif., Sept. 10 Patient Safety ... contract with Partners HealthCare and will be implementing its Safety-Sponge(TM) System ... "Brigham & Women,s has a long tradition of innovation and leadership ... proud of the patient safety research we have done together and ...
... VOORHEES, N.J., Sept. 10 Angioedema is characterized by ... airway, causing discomfort and even death as a result of airway ... and treatment of angioedema, and new therapies are being studied to ... , , To address the need for current ...
... , Calls on Congress to Enact Reform ... Coalition on Liability and Access today commended President Obama for acknowledging ... calls on Congress to follow the President,s leadership by including reform ... night, in an address to Congress, President Obama said, "I,ve talked ...
... , , ... it has established the Edward Neurosciences Institute in affiliation with ... of stroke care in the world to the west and ... http://www.newscom.com/cgi-bin/prnh/20090910/CG73991 ) , , The new Edward ...
Cached Medicine News:Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 2Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 3Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 4Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 5Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 6Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 7Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 8Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 9Health News:Collaborative Research Study Aims to Prevent Firefighter Injury Nationwide 10Health News:Young People at High Risk of Death Worldwide 2Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2Health News:Broad Health Coalition Applauds President Obama's Commitment to Medical Liability Reform 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 3
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... COLUMBUS, Ohio, July 24, 2014  Mettler-Toledo International Inc. ... results for 2014.  Provided below are the highlights: ... in the quarter compared with the prior year. Reported ... currency. , Net earnings per diluted share as ... second quarter of 2013. Adjusted EPS was $2.57, an ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... CT/GC Controls are liquid controls ... of test procedures that detect ... Since they are specimen specific, ... either urine or endocervical/urethral swabs ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: